AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$BHC

Lenar Aimee J. sold $259K of BHC

Lenar Aimee J. (President, US Pharma) sold 36,827 shares of Bausch Health Companies Inc. (BHC) at $7.03 ($0.26M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lenar Aimee J.
Published Aug 20, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BHC
Bearish
medium confidence
Mentioned
$BHC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BHCBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for BHC.

02

Market read

A senior executive's stock sale adds a modest data point for traders monitoring BHC.

03

What to watch

The insider retains a large stake (334,853 shares) indicating continued confidence.

Relevance 3/10Novelty 5/10Timing: post‑market filing on Aug 20

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$BHCBearishMedium confidence
Context

President of US Pharma sold 36,827 shares for $258,894 via a 10b5‑1 plan.

Expected impact

Potential modest downward pressure on BHC stock.

Evidence & confidence

Sale size is modest relative to holdings but involves a senior executive; market may interpret as a slight bearish signal.

Market effects

Sector

Limited impact on the broader pharma sector.

Regional

No significant regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish sign.

Key entities

  • person
    Lenar Aimee J.

    President, US Pharma at Bausch Health Companies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BHC insider trading history →

Related articles

SEP 11
$BHCMed

Bausch + Lomb Receives CE Mark Approval for SeeLyra Femtosecond Laser

Bausch + Lomb received CE Mark approval for its SeeLyra femtosecond laser in Europe, allowing a limited rollout soon and broader availability in 2027. The laser is designed for cataract, LASIK, and corneal procedures, offering precision and flexibility. The company is also seeking approvals in other markets, including the U.S.

eyewire.news2 min
AUG 27
$BHCMed

Bausch + Lomb dry eye combo drop advances to phase 3 evaluation

Bausch + Lomb announced phase 3 plans for a dual-action dry eye drop combining lifitegrast and PFHO, after phase 2 results showed a significant reduction in corneal staining at Day 15. The company also reported positive phase 1b data for BL1332, a TRPV1 antagonist eye drop, showing significant pain reduction in a capsaicin challenge model. Both treatments showed acceptable safety profiles. Phase 2 trials for BL1332 are ongoing.

glance.eyesoneyecare.com2 min
AUG 10
$BHCMedAI 8/10

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.

fool.com6 min